What did Polivy’s clinical trials show (overall effectiveness)?
Polivy (polatuzumab vedotin-piiq) is an antibody-drug conjugate tested in combination regimens for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The key clinical evidence comes from studies where Polivy was paired with chemotherapy plus either rituximab or bendamustine, depending on the treatment setting. Across these trials, Polivy-based regimens produced higher response rates and improved survival outcomes versus control chemotherapy strategies, which is reflected in its later regulatory approvals for specific patient groups. [1][2]
What were the main endpoints (response rate, progression-free survival, overall survival)?
In Polivy’s pivotal trials, the primary measures included tumor response (how many patients’ cancers shrank or disappeared) and time-to-disease progression outcomes such as progression-free survival. Overall survival was also assessed. The overall pattern across studies was that Polivy combinations improved these clinical endpoints compared with chemotherapy alone or other standard comparators. [1][2]
What did the pivotal study data look like in the relapsed/refractory DLBCL setting?
For relapsed/refractory DLBCL, one of the most cited datasets is from the pivotal randomized trial that compared Polivy plus bendamustine and rituximab (often referenced as “BR”) versus placebo plus BR. That study demonstrated improved clinical outcomes with the Polivy regimen, and those results formed part of the basis for approval. [1][2]
How do results differ by line of therapy (earlier vs later relapse)?
Polivy’s studied populations were not all the same. Clinical outcomes can differ depending on whether patients are treated at first relapse versus later relapses, and depending on how many prior therapies they received and whether the disease is refractory. The trial programs for Polivy focused on defined relapsed/refractory groups, and the reported benefits are specific to those eligibility criteria rather than applying uniformly to all DLBCL patients. [1][2]
What side effects came up in the trial results?
Clinical trial reports for Polivy-based regimens include risks that are consistent with chemo-immunotherapy combinations and antibody-drug conjugates. Common safety themes include blood count suppression (neutropenia and other cytopenias), infection risk, and neuropathy, alongside infusion-related reactions and gastrointestinal effects seen with combination chemotherapy partners. The safety profile was incorporated into prescribing information based on the trial experience. [1][3]
Where can I find the exact trial numbers and tables?
Exact figures (for example, the specific response-rate percentages and survival medians) are reported in the prescribing information and associated clinical study publications. Those documents contain the endpoint results and stratifications used in the trials. [1][2][3]
---
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/polivy
- https://www.accessdata.fda.gov/drugsatfda_docs/label/
- https://www.nccn.org/guidelines/